Post-marketing safety signals of the ROCK2 inhibitor Belumosudil for chronic graft-versus-host disease: a real-world disproportionality analysis based on the FAERS database
Objective To characterize the real-world post-marketing safety profile, evidence hierarchy, and demographic vulnerabilities of the selective ROCK2 inhibitor Belumosudil in chronic graft-versus-host disease (cGVHD) using FAERS. Methods Adverse event reports (Q3 2021–Q4 2025) were extracted from FAERS. To control indication confounding, primary disproportionality analysis was anchored to a disease-restricted cGVHD and hematopoietic stem cell transplantation background ( n = 921 , 529 ) using four consensus algorithms (ROR, PRR, BCPNN, MGPS) with False Discovery Rate (FDR) validation. Signals were filtered via a prespecified clinical protocol and stratified into a three-tier evidence framework. Subgroup vulnerabilities (prognostic mortality, age, sex) were evaluated using Fisher’s exact tests. Dual sensitivity analyses evaluated polypharmacy (monotherapy cohort with standardized mean difference [SMD] balance) and denominator stability (whole-database comparator). Results Among 1,797 primary suspect Belumosudil reports (6,056 adverse events), initial screening identified 61 consensus-positive Preferred Terms (PTs); 60 maintained FDR significance ( q < 0.05 ). After systematically excluding 16 confounded administrative and indication-synonymous terms, 45 core PTs were retained across three tiers (Tier 1 trial verification, n = 6 ; Tier 2 novel mechanistic signals, n = 6 ; Tier 3 clinical confounders, n = 33 ). Pharmacological toxicities clustered into three dimensions: musculoskeletal symptoms (muscle tightness, ROR = 10.25; skin swelling, ROR = 19.32), mucosal/viral infections (respiratory syncytial virus, ROR = 4.02; viral gastroenteritis, ROR = 4.81), and laboratory abnormalities (hepatic enzyme increased, ROR = 5.64; blood immunoglobulin G decreased, ROR = 5.75). Subgroup stratification identified distinct clinical vulnerabilities: fatal cases were enriched for obliterative bronchiolitis and muscle atrophy; elderly patients ( ≥ 65 years) exhibited predilection for joint stiffness and lip pain ( P < 0.05 ); and females displayed heightened susceptibility to transaminase elevation, skin atrophy, and oral mucosal blistering ( P < 0.05 ). Monotherapy sensitivity analysis ( N = 1 , 255 ; almost all baseline SMDs < 0.10 ) and whole-database comparison confirmed signal robustness. Conclusion Belumosudil’s real-world safety landscape is dominated by musculoskeletal tightness and edema, mucosal and viral infections, and transaminase/immunoglobulin fluctuations, without novel systemic organ toxicities. Findings underscore the necessity of tailored clinical surveillance: monitoring pulmonary decline in severe disease, joint stiffness in elderly recipients, and hepatic transaminases in females.
Authors
- Yulan Zeng (ORCID: https://orcid.org/0000-0002-6415-1794)
- Tao� Zhang (ORCID: https://orcid.org/0000-0003-4018-3393)
- Junguo Duan (ORCID: https://orcid.org/0009-0009-3858-077X)
- Xiyue Tan
- Ruixia Wang
- Yuxia Liu
- Hao Wu (ORCID: https://orcid.org/0000-0002-5213-2959)
- Fei Wang
- Xueting Wang
Institutions
- Chengdu University (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3389/fimmu.2026.1884204
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00